682 When to start antiresorptive treatment in prostate cancer patients on androgen suppression

2013 ◽  
Vol 12 (1) ◽  
pp. e682
Author(s):  
Garcia D. Lorente ◽  
J. Planas ◽  
A. Celma ◽  
F. Agreda ◽  
C. Konstantinidis ◽  
...  
2002 ◽  
Vol 36 (5) ◽  
pp. 921-926 ◽  
Author(s):  
Mário L de Lemos

OBJECTIVE: To determine the efficacy and toxicity of the herbal supplement PC-Spes in prostate cancer patients. METHODS: Literature search through MEDLINE (1966–October 2001), PubMed, and abstracts from the Annual Meeting of the American Society of Clinical Oncology (1995–2001). RESULTS: PC-Spes was associated with biochemical and clinical response in some prostate cancer patients. The mechanisms of action of PC-Spes appeared to be related to its estrogenic activity. CONCLUSIONS: PC-Spes is associated with some efficacy in prostate cancer patients. Due to the limited data available, it should not be used to replace standard androgen suppression therapy in androgen-dependent patients. PC-Spes may have a role for patients who have failed standard treatments for androgen-independent disease and have no history of thromboembolism or abnormal bleeding. PC-Spes has a toxicity profile similar to those of androgen suppression and estrogen therapy.


2006 ◽  
Vol 5 (2) ◽  
pp. 56
Author(s):  
E. Trilla ◽  
J.M. Abascal ◽  
J. Planas ◽  
A. Orsola ◽  
L. Cecchini ◽  
...  

2006 ◽  
Vol 5 (2) ◽  
pp. 56 ◽  
Author(s):  
J. Planas ◽  
J.M. Abascal ◽  
A. Orsola ◽  
E. Trilla ◽  
C.X. Raventós ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document